This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
PPD signs new in-license deal with Lilly for dapoxetine
21 Jul 2004
Pharmaceutical Product Development (discovery and development services and compound partnering) will acquire from Lilly the patents for dapoxetine for development in the genitourinary field. PPD agrees to pay Lilly $65mm in cash up front, plus a royalty on net sales in excess of a set threshold (reported in industry news as 5% on sales over $800mm a year).
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?